#Japan #Tokyo #cancer screening #N-NOSE #HIROTSU BioScience

N-NOSE 10th Anniversary Celebration: A Decade of Innovation in Cancer Screening

HIROTSU BioScience, founded by CEO Takahiro Hirotsu and headquartered in Chiyoda, Tokyo, is thrilled to announce the "N-NOSE 10th Anniversary Appreciation Event" to celebrate a decade since the invention of the world's first primary screening cancer test, N-NOSE. This special event will take place from June 16, 2025, to July 15, 2025.

The Unmatched Technology of N-NOSE

N-NOSE is an innovative cancer detection method that employs the remarkable olfactory capabilities of C. elegans, a tiny nematode around 1mm long. Renowned for its sense of smell, similar to that of dogs, this organism was harnessed to develop an efficient way to detect cancer through urine samples. The underlying vision driving this research is a world where cancer can be discovered early—prioritizing individuals' health and providing peace of mind for the future.

Established through a thorough four years of clinical research, the reliability of N-NOSE has been validated extensively. Today, we collaborate with various domestic and international research and medical institutions, embodying our commitment to excellence as demonstrated by papers published in global journals and presentations at international conferences.

Cancer Screening Within Reach

One of the significant advantages of N-NOSE is that it allows for the simultaneous screening of 23 types of cancer with just a small urine sample. This non-invasive and simple procedure minimizes physical strain, making it accessible even to those with busy schedules. Over the past few years, N-NOSE has rapidly gained popularity not just among individuals, but also within corporate health management schemes, preventative medical initiatives, and local municipalities.

Gratitude and Future Aspirations

The upcoming appreciation event serves not only as a celebration of the past decade of N-NOSE but also as an opportunity to promote greater awareness of the importance of early cancer detection and prevention. This gratitude extends to all who have supported us throughout these ten years, and our resolve to further our mission into the next decade is stronger than ever.

In honor of this significant milestone, we are offering a first and last chance to purchase N-NOSE services at special appreciation prices, making affordable cancer screening a reality for even more individuals.

Campaign Overview

• - Campaign Name: N-NOSE 10th Anniversary Appreciation Event
• - Campaign Duration: June 16, 2025 - July 15, 2025
• - Offer: Discover exclusive discounts on N-NOSE services during this limited-time event.

Regular Rates vs. Special Appreciation Prices:

• - Regular N-NOSE check-up: ¥15,800 → Special: ¥10,800 (¥5,000 Off)
• - One-time N-NOSE test: ¥16,800 → Special: ¥11,800 (¥5,000 Off)
• - N-NOSE Plus (pancreatic cancer): ¥70,000 → Special: ¥35,000 (¥35,000 Off)
• - N-NOSE for pets (regular): ¥22,800 → Special: ¥12,800 (¥10,000 Off)
• - N-NOSE for pets (one-time): ¥23,800 → Special: ¥13,800 (¥10,000 Off)

Access the special campaign page through our N-NOSE service site or via the provided QR code to enter your coupon code when applying.

For 10 years, we have committed to making the frightening idea of cancer more manageable. Let us establish cancer screening as a vital part of everyone’s health care routine. Embracing our gratitude for the past, we look forward to walking together into a healthier future.

About HIROTSU BioScience

HIROTSU BioScience aims to protect people’s health and future through the research, development, and practical application of innovative cancer screening technologies using biological capabilities. Established in August 2016, we successfully brought N-NOSE to market due to the creativity and relentless efforts of our researchers. In a society where 1 in 2 individuals are likely to develop cancer, our advanced technology harnesses the exceptional olfactory abilities of C. elegans to address this pressing social issue.

Key Information

• - Company Name: HIROTSU BioScience
• - Location: 22nd Floor, New Otani Garden Court, 4-1 Kioicho, Chiyoda, Tokyo
• - CEO: Takahiro Hirotsu
• - Founded: August 2016
• - Core Business: Research, development, and sale of cancer tests utilizing C. elegans and olfactory sensors.
• - Corporate Website: HIROTSU BioScience

About N-NOSE

Utilizing the exceptional sense of smell of C. elegans, N-NOSE provides a simple and cost-effective cancer screening solution, using only urine samples to comprehensively check for early cancer risks.

• - Service Site: N-NOSE Service

About N-NOSE Plus

N-NOSE Plus is a next-generation cancer type-specific test. It employs genetically modified C. elegans that respond specifically to certain cancer odors, enabling precise risk assessment while remaining non-invasive. Currently, it focuses on pancreatic and liver cancer risks.

• - Service Site: N-NOSE Plus Service

About N-NOSE Animal

This service applies N-NOSE technology to canine and feline cancer detection, offering the first easy cancer screening available for pet owners by analyzing urine samples—a comfortable solution for animals who can't express symptoms.

• - Service Site: N-NOSE Animal Service